Moderna Inc (MRNA)

[axelvento]

William Blair analyst Myles Minter cited "administration constraints" at the FDA for the delay.

"Although regulatory delays are disappointing and usually create noise around the probability of approval, given the 'administrative constraints' information currently available and known FDA backlogs, today's news does not alter our expectation that (Moderna's RSV vaccine) will receive approval under the current (biologics license agreement) review cycle," he said in a report.